Strongbridge Biopharma Plc Quick Ratio (SBBP) starting from the second quarter 2021 to second quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Strongbridge Biopharma plc  (NASDAQ: SBBP)

Strongbridge Biopharma Plc's Quick Ratio

SBBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2021, Quick Ratio deteriorated to 7.36 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 276 other companies have achieved higher Quick Ratio than Strongbridge Biopharma Plc in second quarter 2021. While Quick Ratio total ranking in the second quarter 2021 has deteriorated compared to the prior quarter from 405 to 927.

Explain Quick Ratio?
How much Cash & cash equivalents SBBP´s has?
What are SBBP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SBBP Quick Ratio (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2
Y / Y Current Liabilities Change 2.95 % -61.46 % -43.52 % -5.75 % 17.81 %
Y / Y Cash & cash equivalent Change 6.45 % 17.58 % 12.06 % 2.74 % -30.47 %
Quick Ratio MRQ 7.36 7.46 16.21 10.67 7.12
SBBP's Total Ranking # 927 # 405 # 60 # 69 # 92
Seq. Current Liabilities Change -12.51 % 83.42 % -29.6 % -8.87 % -67.25 %
Seq. Cash & cash equivalent Change -13.7 % -15.57 % 7 % 36.53 % -4.67 %



Quick Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 277
Healthcare Sector # 450
Overall Market # 927


Quick Ratio Statistics
High Average Low
16.21 7.32 2.45
(Dec 31 2020)   (Mar 31 2020)




Financial Statements
Strongbridge Biopharma Plc's Current Liabilities $ 9 Millions Visit SBBP's Balance sheet
Strongbridge Biopharma Plc's Cash & cash equivalent $ 64 Millions Visit SBBP's Balance sheet
Source of SBBP's Sales Visit SBBP's Sales by Geography


Cumulative Strongbridge Biopharma Plc's Quick Ratio

SBBP's Quick Ratio for the trailling 12 Months

SBBP Quick Ratio

 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth -38.94 % -37.89 % 30.37 % 17 % -12.13 %
Y / Y Cash & cash equivalent TTM Growth 9.46 % -1.17 % -16.12 % -28 % -26.26 %
Quick Ratio TTM 9.71 9.66 6.19 5.51 5.41
Total Ranking TTM # 4500 # 4496 # 4516 # 704 # 4538
Seq. Current Liabilities TTM Growth 0.79 % -33.47 % -8.1 % -0.9 % 2.52 %
Seq. Cash & cash equivalent TTM Growth 1.28 % 3.78 % 3.33 % 0.78 % -8.56 %

Quick ratio ranking by company, industry and sector >> Back to SBBP Financial Strength Comparisons >> Go to Compare SBBP Quick Ratio to its Competitors

On the trailing twelve months basis SBBP Cash & cash equivalent improved by 6.45 % in Q2 2021 year on year, faster than Current Liabilities, this led to increase in in Strongbridge Biopharma Plc's Quick Ratio to 9.71, above SBBP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 502 other companies have achieved higher Quick Ratio than Strongbridge Biopharma Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2021 from 4496 to 4500.

Explain Quick Ratio?
How much Cash & cash equivalents SBBP´s has?
What are SBBP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 503
Healthcare Sector # 990
Within the Market # 4500


trailing twelve months Quick Ratio Statistics
High Average Low
8.75 4.99 3.18
(Mar 31 2016)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2021 MRQ Cash & cash equivalentJun 30 2021 MRQ Current Liabilities
Shattuck Labs Inc   20.17 $ 304.798  Millions$ 15.111  Millions
Protagenic Therapeutics Inc new  19.80 $ 11.933  Millions$ 0.603  Millions
Inozyme Pharma Inc   19.72 $ 137.464  Millions$ 6.972  Millions
Equillium Inc   19.61 $ 97.643  Millions$ 4.980  Millions
Jade Biosciences Inc   19.44 $ 59.150  Millions$ 3.042  Millions
Pds Biotechnology Corp  19.44 $ 74.749  Millions$ 3.845  Millions
Merrimack Pharmaceuticals Inc  19.31 $ 14.909  Millions$ 0.772  Millions
Agios Pharmaceuticals Inc   19.05 $ 969.124  Millions$ 50.878  Millions
Anaptysbio Inc   18.96 $ 390.851  Millions$ 20.616  Millions
Neubase Therapeutics inc   18.82 $ 59.096  Millions$ 3.140  Millions
Ovid Therapeutics Inc   18.81 $ 212.344  Millions$ 11.290  Millions
Dianthus Therapeutics Inc   18.75 $ 207.805  Millions$ 11.083  Millions
Neximmune Inc   18.75 $ 102.796  Millions$ 5.483  Millions
Korro Bio Inc   18.70 $ 168.889  Millions$ 9.031  Millions
Matinas Biopharma Holdings Inc   18.62 $ 59.843  Millions$ 3.213  Millions
Viracta Therapeutics Inc   18.61 $ 122.721  Millions$ 6.595  Millions
Seres Therapeutics Inc   18.26 $ 214.553  Millions$ 11.748  Millions
Oncternal Therapeutics Inc   18.07 $ 103.663  Millions$ 5.738  Millions
Viking Therapeutics Inc   18.01 $ 228.258  Millions$ 12.673  Millions
Processa Pharmaceuticals Inc   17.94 $ 20.831  Millions$ 1.161  Millions
Oragenics Inc   17.91 $ 34.575  Millions$ 1.930  Millions
Climb Bio Inc   17.81 $ 99.482  Millions$ 5.586  Millions
Calcimedica Inc   17.77 $ 73.586  Millions$ 4.141  Millions
Enveric Biosciences Inc   17.66 $ 20.618  Millions$ 1.168  Millions
Otonomy Inc   17.65 $ 97.878  Millions$ 5.546  Millions
Rain Enhancement Technologies Holdco Inc   17.64 $ 164.647  Millions$ 9.336  Millions
Xenon Pharmaceuticals Inc   17.39 $ 260.523  Millions$ 14.982  Millions
Immunome Inc   17.21 $ 59.829  Millions$ 3.477  Millions
Benitec Biopharma Inc   17.11 $ 19.778  Millions$ 1.156  Millions
Atrium Therapeutics Inc   17.10 $ 279.458  Millions$ 16.338  Millions

Date modified: 2026-09-08T15:10:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.